Adjuvant Therapy for Renal Cell Carcinoma: Past, Present, and Future

被引：48

作者：

Pal, Sumanta K. ^{[1
]}

Haas, Naomi B. ^{[2
]}

机构：

[1] City Hope Natl Med Ctr, Ctr Comprehens Canc, Dept Med Oncol & Expt Therapeut, Duarte, CA USA

[2] Univ Penn, Sch Med, Dept Med, Philadelphia, PA 19104 USA

来源：

ONCOLOGIST | 2014年 / 19卷 / 08期

关键词：

Adjuvant; Renal cell carcinoma; ASSURE; SORCE; S-TRAC; PROTECT; EVEREST; POSITIVE BREAST-CANCER; PHASE-III; INTERFERON-ALPHA; POSTMENOPAUSAL WOMEN; RADICAL NEPHRECTOMY; HIGH-RISK; INTERLEUKIN-2; TAMOXIFEN; VACCINE; TRIAL;

D O I：

10.1634/theoncologist.2014-0105

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

At the present time, the standard of care for patients who have received nephrectomy for localized renal cell carcinoma (RCC) is radiographic surveillance. With a number of novel targeted agents showing activity in the setting of metastatic RCC, there has been great interest in exploring the potential of the same agents in the adjuvant setting. Herein, we discuss the evolution of adjuvant trials in RCC, spanning from the immunotherapy era to the targeted therapy era. Pitfalls of current studies are addressed to provide a context for interpreting forthcoming results. Finally, we outline avenues to incorporate promising investigational agents, such as PD-1 (programmed death-1) inhibitors and MNNG transforming gene inhibitors, in future adjuvant trials. The Oncologist 2014; 19: 851-859

引用

页码：851 / 859

页数：9

共 65 条

[1]

Amin A, 2010, J CLIN ONCOL, V28, p4588a

[2]

[Anonymous], J CLIN ONCOL S

[3] Adjuvant treatment with interleukin-2-and interferon-alpha2a-based chemoimmunotherapy in renal cell carcinoma post tumour nephrectomy:: Results of a prospectively randomised Trial of the German Cooperative Renal Carcinoma Chemoimmunotherapy Group (DGCIN) [J].

Atzpodien, J ;

Schmitt, E ;

Gertenbach, U ;

Fornara, P ;

Heynemann, H ;

Maskow, A ;

Ecke, M ;

Wöltjen, HH ;

Jentsch, H ;

Wieland, W ;

Wandert, T ;

Reitz, M .

BRITISH JOURNAL OF CANCER, 2005, 92 (05) :843-846

[4]

Belldegrun AS, 2013, J CLIN ONCOL, V31

[5]

Brannon A Rose, 2010, Genes Cancer, V1, P152

[6] Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials [J].

Buzdar, A ;

Jonat, W ;

Howell, A ;

Jones, SE ;

Blomqvist, C ;

Vogel, CL ;

Eiermann, W ;

Wolter, JM ;

Azab, M ;

Webster, A ;

Plourde, PV .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (07) :2000-2011

[7]

Choueiri TK, 2012, J CLIN ONCOL S, V30, p4504a

[8] Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy [J].

Choueiri, Toni K. ;

Regan, Meredith M. ;

Rosenberg, Jonathan E. ;

Oh, William K. ;

Clement, Jessica ;

Amato, Angela M. ;

McDermott, David ;

Cho, Daniel C. ;

Atkins, Michael B. ;

Signoretti, Sabina .

BJU INTERNATIONAL, 2010, 106 (06) :772-778

[9] Validation by calibration of the UCLA Integrated Staging System prognostic model for nonmetastatic renal cell carcinoma after nephrectomy [J].

Cindolo, Luca ;

Chiodini, Paolo ;

Gallo, Ciro ;

Ficarra, Vincenzo ;

Schips, Luigi ;

Tostain, Jacques ;

de la Taille, Alexandre ;

Artibani, Walter ;

Patard, Jean Jacques .

CANCER, 2008, 113 (01) :65-71

[10] Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: A cytokine working group randomized trial [J].

Clark, JI ;

Atkins, MB ;

Urba, WJ ;

Creech, S ;

Figlin, RA ;

Dutcher, JP ;

Flaherty, L ;

Sosman, JA ;

Logan, TF ;

White, R ;

Weiss, GR ;

Redman, BG ;

Tretter, CPG ;

McDermott, D ;

Smith, JW ;

Gordon, MS ;

Margolin, KA .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (16) :3133-3140

← 1 2 3 4 5 6 7 →